VOSTOK ONE https://vostok.one ru Wed, 26 Aug 2026 22:02:05 +0300 The Man Who Bench-Presses 100kg... https://vostok.one/tpost/ms-denis-story https://vostok.one/tpost/ms-denis-story?amp=true Tue, 30 Jun 2026 00:02:00 +0300 Simon Einstein ...and What That Has to Do with Drug Discovery? On the 13th of February 2026, Denis Milov walked out of a Moscow hospital — not for the first time. Four days of tests, an MRI, the usual neurology ward routine.

The Man Who Bench-Presses 100kg...

The verdict: remission. No new lesions. No disease progression since the previous scan.
For most patients, this would be unremarkable. For Denis, it was the latest data point in an experiment that has been running for sixteen years — with his own body as the subject.
The first sign was an eye twitch. Barely noticeable at first. Then it became a full facial spasm — every fifteen seconds, around the clock. He would fall asleep only from sheer exhaustion. Then came the coordination problems. He stopped being able to walk without support. He lost fourteen kilograms. On windy days, gusts knocked him to the ground.

Every few months, he quietly looked for freelance work — anything to ease the financial weight on his family, to feel less like a burden to the wife and children who were watching him disappear.

"I thought I was going to die," he says.

Interferon, the standard treatment he had been prescribed, kept the acute relapses at bay. But it could not stop what was happening underneath: the slow, relentless erosion of neurological function that defines the progressive face of this disease. This is the problem that has haunted MS medicine for decades. We learned to fight the fire. We never learned to rebuild what burned.
There are approximately three million people living with multiple sclerosis worldwide. One is diagnosed every five minutes. The disease most commonly strikes between 30 and 59 — the years when people are building careers, raising families, running companies.

The last decade brought genuine advances. Anti-CD20 biologics changed the prognosis for primary progressive MS. A new class of oral therapies — BTK inhibitors — is now in late-stage trials, and the first provisional approval in the UAE was granted in July 2025. These drugs reach compartmentalised inflammation deep inside the central nervous system, further than any previous treatment could.

But even the best of them leaves one question unanswered. Leading clinical research organisations note in their latest analyses: "disability progression often occurs independently of relapse activity." Stopping the inflammation does not restore what was already lost.

The next frontier is not suppression. It is regeneration.

There is something else that rarely gets said plainly. Multiple sclerosis is not considered a hereditary disease — but that is not entirely accurate. Research in several countries shows a meaningful genetic predisposition, with children of MS patients facing substantially higher risk. Early screening — before symptoms appear, before a first MRI reveals what should have been caught earlier — changes the equation entirely. For a young person with a predisposition, timely intervention means the difference between a life that unfolds and a life that must be
fought for, centimetre by centimetre, for decades.
Denis arrived at this conclusion not through a literature review, but through his own recovery.

He began training — obsessively, systematically. Large muscle groups, every day, building mass against the illness that was steadily trying to reclaim it. And slowly, something happened that no doctor had predicted: neurological function began to improve. Not in a way that any single scan could capture as a miracle. But measurably, over years.

Today, Denis bench-presses 100 kilograms. His most recent MRI shows no new lesions — a picture that has been stable across multiple scans since 2020. His EDSS score, the standard clinical measure of MS-related disability, is 4.0: he walks more than a kilometre without assistance. For someone who once could not walk at all, and who has lived with active MS for sixteen years, this is not nothing.

The biology behind it points toward a precise mechanism.

Intensive resistance training is one of the most reliable stimulants of IGF-1 — insulin-like growth factor 1. IGF-1, in turn, has documented neuroprotective properties: it promotes neuronal survival and supports the repair of myelin, the insulating sheath that MS progressively destroys. Denis did not design a clinical trial.

He risked his life to find out the answer: was it possible to lift his head? To sit up in the hospital bed? To stand, and take the first steps? To come back to life.
Denis and his team launched a biotech research venture in the United Arab Emirates — VOSTOK ONE, incorporated at Masdar City in Abu Dhabi — which is now running the science.

The MS programme is part of a broader portfolio brought together by the scientists who gave Denis a second chance. The question the programme is designed to answer is precise: can IGF-1-based intervention systematically stimulate the neurological repair that Denis experienced individually? Can it be made into a reproducible, scalable medicine — safe and effective enough for regulatory approval? That is the work. It proceeds at the pace that serious drug development requires methodical, evidence-bound, and grounded in biology that was tested on a human being before it was ever written into a research protocol.

The goal is not to help people cope. It is to bring them back — to work, to family, to movement, to the life that MS takes away so gradually that some people barely notice what they've lost until it's gone. Denis walked this path alone, for sixteen years, through stubbornness and a barbell and a piece of biology he understood before science had named it. The technology VOSTOK ONE is developing is designed to make that path available to those who don't have his willpower, his time — or his luck.
Multiple sclerosis is diagnosed every five minutes across the Earth. Three million people are waiting for something that does more than slow the damage.

Denis Milov is one of them. He is also, now, one of the people working on the answer.
VOSTOK ONE is a frontier biotechnology holding incorporated at Masdar City, Abu Dhabi. The company develops and out-licences pre-IND-enabling therapeutic programmes across neurology, oncology, and longevity. Out-licensing & Partnerships: vostok.one
]]> After a Stroke, the Clock ticks louder https://vostok.one/tpost/f0m8gi8y71-after-a-stroke-the-clock-ticks-louder https://vostok.one/tpost/f0m8gi8y71-after-a-stroke-the-clock-ticks-louder?amp=true Wed, 15 Jul 2026 15:03:00 +0300 True story with no happy end. Three days ago, a man from a neighbouring building died. His name was Sasha.

After a Stroke, the Clock ticks louder

Sasha worked in music production: helping artists get up on the big stage, arranging tours across the country, turning phone calls, venues, rehearsals and agreements into a working process. It wasn't the glamorous side of the industry, where names become known overnight. It was the daily grind — calls, small venues, long drives, and the painstaking work of getting an artist in front of an audience.

His health had been shaky for a while. Last year, Sasha was diagnosed with a stroke, and disability status followed. Then came the life familiar to so many post-stroke patients: hospital, drips, medication, the daily fistful of tablets, the clinic, exhaustion, anxiety, and the nagging feeling that his body could no longer be trusted the way it used to be.

The illness reshaped his family too. His wife left. Sasha was raising his teenage son alone — a boy who'd just finished school with excellent results and was getting ready for university.

We’d run into each other now and then — in the courtyard, outside the clinic, in those ordinary little moments and corners where neighbours talk about blood pressure, sleep, nerves, doctors, prescriptions, and whatever the body no longer lets you ignore.
Yesterday, our neighbour from the residents' committee called.

"Sasha's gone," he said. "We spoke to him three hours ago. Then he went into the kitchen, and his heart stopped."

And today, in the courtyard, his children were going through his things in his car.

That’s how stroke statistics enter ordinary life. Not as a percentage. Not as a chart. As a car being emptied out by children who should never have had to do this so young.

Medically speaking, one phone call can’t establish that Sasha's death was caused by his stroke — that would be jumping to conclusions. But medicine is quite clear about something else: after an ischaemic stroke, the danger doesn’t end the moment the patient walks out of hospital.

Stroke remains one of the leading causes of death and disability worldwide. In 2021, global stroke prevalence was estimated at 93.8 million people, with 11.9 million new strokes and 7.3 million stroke-related deaths that year. Ischaemic stroke is the most common type by far, accounting for around 65.3% of all cases.[1]

But a stroke isn’t a single moment. It’s a sequence.

First, a vessel closes. Then a patch of brain is starved of oxygen and energy. Then the injury cascade kicks in — inflammation, excitotoxicity, oxidative stress, swelling, reperfusion injury. Some cells die fast. Others are left hanging — no longer healthy, but not yet irreversibly lost. It’s in that narrow window that treatment can still change how it all ends.

Modern medicine has made real headway on the first half of that sequence. Thrombolytics can dissolve clots. Mechanical thrombectomy can remove them. Stroke units, emergency care and well-run hospital routes have saved plenty of lives and cut down on disability.
But reopening a vessel isn’t the same as saving the brain.
And leaving hospital isn’t the same as recovering
DATA POINT

After a stroke, a person stays at risk medically. A large Japanese national study of 18,719 patients with non-cardioembolic ischaemic stroke or transient ischaemic attack found a recurrent ischaemic stroke rate of 103.5 events per 1,000 patient-years. After a first recurrence, the risk climbed even higher: the rate of a further ischaemic stroke reached 199.9 per 1,000 patient-years, death 53.3, myocardial infarction or unstable angina 39.6. Time to death was shorter after recurrence too — a median of 255 days, against 366 days after the first event. And only 54.2% of patients had received any antithrombotic therapy at all in the 90 days before their first recurrence.[2]
These numbers matter for more than their own sake. What they really show is this: after a first stroke, a person doesn’t step out of danger — they step into a new vascular reality, where recurrence, bleeding risk, other conditions, treatment adherence problems and general physical exhaustion all become part of the same risk.

For the patient, that can look like weakness, memory trouble, medication, rehabilitation, fear of it happening again, lost work, lost independence — and a quiet fear running through the family, flinching at every unexpected phone call.

But there are treatments. The question isn’t only how to reopen a blocked vessel — it's how to protect vulnerable nerve tissue, limit the damage that follows, and improve the odds that someone comes back with less disability.
VOSTOK ONE / VO-IS01

That’s exactly where VOSTOK ONE and its scientific team have focused their work, developing VO-IS01 — a promising candidate against ischaemic stroke. It sits at the pre-GLP stage as a pre-IND-enabling therapeutic programme. At the heart of the work is a narrower, more testable question: can a therapeutic intervention be built that protects vulnerable brain tissue during or after acute ischaemic injury — before temporary damage turns into permanent disability?

Developing stroke drugs is hard. The treatment window is short. Patients don't fit neatly into one category. Trial design has to account for timeframes, when treatment starts, stroke severity, standard care, and unforgiving functional endpoints — the modified Rankin Scale at 90 days, for one. Safety demands are especially high, above all around bleeding and vascular risk.

There’s real progress in this space. Pharmaceutical interest in stroke neuroprotection is growing wherever there's precise biotechnology and a testable rationale behind the science. For VOSTOK ONE, VO-IS01 isn’t a comment on a big medical problem — it's a potentially licensable pharmaceutical asset in an area where the need for treatment stays high, and the cost of getting it wrong isn’t measured in money.

There’s no happy ending to this story. No recovery arc, no scan showing years of stability, no closing shot of triumph. There’s a death at 56 — and a reminder that a long life isn’t handed to you by default. It’s a biological problem you have to fight for — through prevention, treatment, precision medicine, and research that should one day give doctors more options than they have now. For VOSTOK ONE, stories like this don't prove anything scientifically. They don't replace data. They don't make a molecule work.
But they remind everyone why this work is being done in the first place. We all hope to live to a ripe old age — maybe even a hundred. But life has its own plans for us. Sasha was only 56, and today his children were going through his things in his car in the courtyard. Perhaps his story, and the memory of him, is one more reason for this team to keep pushing forward in the research on treating and preventing ischaemic stroke.
SOURCES

[1]: Hirano T. et al. *Antithrombotic therapy, vascular events and mortality after non-cardioembolic ischaemic stroke: a nationwide hospital-based cohort study in Japan*. Stroke & Vascular Neurology, 2026. Introduction, citing GBD 2021.

[2]: Hirano T. et al. *Stroke & Vascular Neurology*, 2026. Abstract, Results and Table 5.
VOSTOK ONE

VOSTOK ONE is a frontier biotechnology holding incorporated at Masdar City, Abu Dhabi. The company develops and out-licenses pre-IND-enabling therapeutic programmes across neurology, oncology, and longevity. Out-licensing & Partnerships: vostok.one
]]> Generations & Survival: a global health crisis in three acts https://vostok.one/tpost/7e0rui7501-generations-amp-survival-a-global-health https://vostok.one/tpost/7e0rui7501-generations-amp-survival-a-global-health?amp=true Wed, 05 Aug 2026 23:37:00 +0300 PART I: a generation without a horizon

Generations & Survival: a global health crisis in three acts

There's a service in Tokyo nobody talks about openly. A young man pays $150–230 for a stranger to come to his flat: to tidy up, cook, listen. No romance, just care. The Japanese call it "dzukujo", and behind it sits not an oddity but a diagnosis. The country's fertility rate has fallen to 1.2. Japan isn't dying out because it doesn't want children. It has forgotten how to be together.
Japanese psychology named this condition decades ago: "amae", the unconscious wish to stay a child someone else takes care of. A generation raised without emotional contact at home doesn't fear loneliness. It fears responsibility. But this isn't a Japanese problem. It's a global shift wearing different faces in different countries.

China spent thirty years enforcing a one-child policy, and is now living with the consequences: later first births, a rapidly ageing population, a demographic hole no single generation can refill. Russia is testing a different model. Its maternity capital programme, launched in 2006, has reached more than 11 million families. It didn't change the culture. It changed the arithmetic. Where having a child stops being a financial risk, people are more willing to have one.

South Korea holds the world's grimmest record: 0.72 children per woman in 2023, the lowest fertility rate ever recorded anywhere. Over sixteen years the government has poured more than 280 trillion won (roughly $210 billion) into incentive programmes, and the rate has crept back up, to 0.80 by 2025. But in Seoul, the country's most expensive city, it still sits at around 0.55. Subsidies soften the arithmetic. They don't cancel it out where the cost of a child outweighs any payment.

Across the Gulf states, a large family remains a living institution, not a museum piece. At the opposite pole is the United States, where the childfree movement has moved from subculture to social norm. Individual choice is respected. Its collective consequences are not yet reckoned with.
The one real counterpoint in this picture is Africa. Niger: 6.7 children per woman. By 2050 the continent will be home to 2.5 billion people with a median age of 25. But that's a continental average, not an urban one: nearly half of Africans already live in cities, and there the curve tracks the rest of the world: a generation that raised 8 to 10 children is giving way to one that wants two or three. Dakar, one of Africa's densest cities, is a case in point. What keeps Niger's birth rate high isn't culture. It's that urbanisation hasn't reached it yet. But youth without education, without jobs, and without adequate healthcare isn't a demographic asset. It's a crisis deferred.

These aren't isolated stories. The UN projects that population has already peaked in 63 countries, including Japan, China and Russia (three cases already in this article). Globally, the population will keep growing for another six decades, reaching 10.3 billion by 2084, before it starts to fall. This crisis isn't national. It's structural, and it's already under way.

There's an unexpected biological parallel to this shift. In 1968, the zoologist John Calhoun placed a colony of mice in an enclosure with unlimited food, water and no predators: the only constraint was space. The colony grew to 2,200 animals, then, at peak density, the mice began losing interest in mating and raising young. Infant mortality reached 100%, the birth rate hit zero, and by 1973 the colony had died out entirely, amid total abundance. Scientists dispute a direct read-across to humans, but the observation lines up: poverty isn't what kills fertility. Density and comfort can do the same job.
*"When young people stop having children, it's neither rebellion nor freedom. It's a symptom. We are biologically built to reproduce, and refusing that hits the psyche harder than any workplace stress," said Denis Milov, VOSTOK ONE.
But the real question isn't only whether children are being born. It's who will pay for the ones already alive and who will treat them.
Sources

1. Statistics Bureau of Japan — Total Fertility Rate 2025
2. World Population Review — Birth Rate by Country 2026
3. Russian Pension Fund / Rosstat — Maternity Capital Programme, 2006–2026 results
4. Statistics Korea — Total Fertility Rate 2023–2025; Seoul Metropolitan Government — fertility rate by district, 2023
5. UN World Population Prospects 2024 — global population peak (2084) and countries with already-peaked population
6. Calhoun, J.B. — "Population Density and Social Pathology" (Scientific American, 1962) + Universe 25 experiment (NIMH, 1968–1972)
7. OECD / African Development Bank / UCLG Africa — "Africa's Urbanisation Dynamics 2025" report
]]> Generations & Survival: A global health crisis in three acts https://vostok.one/tpost/bu53cmpeb1-generations-amp-survival-a-global-health https://vostok.one/tpost/bu53cmpeb1-generations-amp-survival-a-global-health?amp=true Fri, 14 Aug 2026 08:40:00 +0300 Part II: A system under strain

Generations & Survival: A global health crisis in three acts

In 2024, a large US clinic network stopped admitting patients after a cyberattack. Not a data leak. A clinical shutdown. In the first half of 2026, US healthcare recorded 281 breaches, second only to the financial sector's 387. Hospitals have become target number two. The deeper the digitisation, the wider the attack surface. And demographic pressure only raises the stakes: more elderly patients means more records, more connected devices, more vulnerabilities.

A parallel crisis is unfolding. In the US, the economic cost of opioid addiction reached $2.7 trillion in 2023 alone. 107,000 overdose deaths that year. This isn't a drug problem. It's a failure of pain management. Modern medicine has learned to save people with severe trauma. They survive, and return with chronic pain a doctor can treat with little beyond morphine. There are almost no alternatives. The pharmaceutical market is short on next-generation, non-opioid analgesics capable of breaking that chain.

Sweden shows what a working model looks like. The effective retirement age is 67 and rising. Active longevity here isn't a slogan. It's a government programme that's been running for two decades. Workers don't stop in a single day; they wind down gradually. The economy wins, and the person stays needed.
Germany is moving the other way: a pension shortfall, a labour shortage, and labour migration used as a temporary patch over a structural wound. Japan is its own case entirely: the country with the world's longest-lived population also holds the record for overwork. "Karoshi" (death from overwork) is a Japanese term with no exact translation elsewhere, because nowhere else has quite got there yet.
Africa stands apart. Fewer than three doctors per 10,000 people, against more than 36 in Europe. A predator doesn't chase the strongest prey. It goes where the defences are weakest: in Europe, attacks have moved from servers to cars, and then to IoT devices, as each frontier hardened in turn. Senegal has weathered attacks on its tax authority, interior ministry and treasury within a single year. Africa's low digitisation isn't a shield against cyberattacks, only a matter of time. But the real threat here isn't that. It's the absence of a healthcare system at all. Up to 30% of medicines on the continent are counterfeit. A cancer patient gets paracetamol where they need biologic therapy. That's not a logistics problem. It's a political one.
"Population ageing isn't just a medical problem. It's a fiscal one. Every year of delay costs national economies more than their entire annual budget," said Igor Porfiliev, VOSTOK ONE.
Systems that can't cope with a working generation will inherit a generation that can no longer work. And here, different cultures give fundamentally different answers.
VOSTOK ONE is a drug development platform. The company advances pre-IND-enabling therapeutic programmes across neurology, oncology and longevity for licensing and strategic partnerships. vostok.one
Sources
1. Identity Theft Resource Center — H1 2026 Data Breach Report (cross-referenced with HHS Office for Civil Rights breach portal)
2. CDC NCHS Data Brief No. 549 — overdose deaths, 2023 · White House / ONDCP, March 2025 — economic cost of illicit opioids, 2023
3. OECD, Pensions at a Glance 2023 country note (Sweden) — guarantee pension age reaching 67 in 2026; Pensions at a Glance 2025 — future normal retirement age trending to 70+
4. WHO Global Health Observatory — Medical doctors (per 10,000 population), by region
5. Senegal government cyberattack reports, Oct 2025 – May 2026 (Tax Authority / DGID, Interior Ministry, Treasury / DGCPT) — RFI/AllAfrica, APAnews, SearchInform
]]> Generations & Survival: A global health crisis in three acts https://vostok.one/tpost/generations-survival-part-iii-price-of-a-long-life https://vostok.one/tpost/generations-survival-part-iii-price-of-a-long-life?amp=true Wed, 26 Aug 2026 11:58:00 +0300 Part III: The price of a long life

Generations & Survival: A global health crisis in three acts

In Norway, a place in a state care home for the elderly costs $100,000 a year per person. Japan has an old legend about obasute: the practice of carrying the elderly into the mountains to die once they became a burden. A legend. But modern Japan records around 80,000 cases of "lonely death" (kodokushi) every year: someone dies at home and goes unnoticed for weeks. That's not cruelty. It's the consequence of intergenerational ties wearing down to nothing.


The opposite pole is the Caucasus. Abkhazia, Georgia, and the mountain regions of Azerbaijan hold some of the world's highest concentrations of centenarians. The secret, it turns out, is embarrassingly simple: intact social ties, contact between generations, physical work well into old age, and, above all, a sense of being needed. Here, an elder is an asset, not a burden.


Gulf states understand this at government level too. The Hevolution Foundation (Saudi Arabia) invests $1 billion a year in biological ageing research. Not philanthropy. Strategy. The region is betting that its population will live to see the next century in sound mind and body.


2026 science is giving these efforts a molecular foundation. In May, Nature published a study covering more than 11,000 transcriptomes across 25 tissues from mice, rats, macaques and humans, identifying conserved ageing signatures that operate the same way across all mammals. In July, the same journal reported 29 genetic loci, known as VITA, that govern mortality within specific age windows: the genes that kill at 60 differ from the ones that kill at 75. Ageing isn't a single process. It's a series of programmes, each with its own switch.


One of the most promising avenues is the fight against senescent cells: biological rubbish, cells that have stopped dividing but haven't died. They accumulate and poison surrounding tissue with inflammation, and that build-up is ageing at the cellular level. A vaccine-based approach to clearing them is unconventional, which is exactly why the market finds it interesting. That same market has already put $4.2 billion in private capital into longevity biotech over three years.


"In cultures where an elder is an asset, not a burden, demographic crises are solved differently. The family as an institution is the oldest form of social insurance we have, and we dismantled it without inventing anything better," said Ibrahim Diane, VOSTOK ONE.
Germany is moving the other way: a pension shortfall, a labour shortage, and labour migration used as a temporary patch over a structural wound. Japan is its own case entirely: the country with the world's longest-lived population also holds the record for overwork. “Karoshi” (death from overwork) is a Japanese term with no exact translation elsewhere, because nowhere else has quite got there yet.


Africa stands apart. Fewer than three doctors per 10,000 people, against more than 36 in Europe. A predator doesn't chase the strongest prey. It goes where the defences are weakest: in Europe, attacks have moved from servers to cars, and then to IoT devices, as each frontier hardened in turn. Senegal has weathered attacks on its tax authority, interior ministry and treasury within a single year. Africa's low digitisation isn't a shield against cyberattacks, only a matter of time. But the real threat here isn't that. It's the absence of a healthcare system at all. Up to 30% of medicines on the continent are counterfeit. A cancer patient gets paracetamol where they need biologic therapy. That's not a logistics problem. It's a political one.
]]>